ENRIGHT PATRICK G sold $75.2M of MANE (indirect holdings)

ENRIGHT PATRICK G sold 500,000 indirectly-held shares of Veradermics, Inc (MANE) at $150.38 ($75.19M total) across 2 trades on 2026-11-11.

Original reporting
SEC EDGAR · ENRIGHT PATRICK G
Published Nov 13, 2026, 10:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 10:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MANE
Bearish
high confidence
Mentioned
$MANE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MANEBearishMed
01

Why it matters

The director's $75M sale is a material event that can influence short-term price dynamics and investor sentiment.

02

Market read

A large insider sell by a director is a notable signal for traders, potentially prompting short positions or cautionary stance.

03

What to watch

Potential tax planning or diversification motives for the director; no disclosed negative news about the business.

Relevance 6/10Novelty 8/10Timing: after-market today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for material ownership changes.

Company-level read

Ticker impact

$MANEBearishHigh confidence
Context

Director Patrick G. Enright sold 500,000 shares for $75.2M, reducing his stake to 1.8M shares.

Expected impact

likely pressure as investors price in the $75M insider sale

Evidence & confidence

The sale represents a significant ownership reduction by a senior insider, which markets typically view as a bearish signal.

Market effects

Healthcare sector may face slight scrutiny as insider activity raises questions about governance.

U.S. investors may adjust exposure to Veradermics based on the director's sell.

Limited to the company; no broader global market effect.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals, offering a buying opportunity.

Key entities

  • Veradermics, Inc.

    Biopharmaceutical company listed on NASDAQ under ticker MANE.

  • Patrick G. Enright

    Director of Veradermics who executed the insider sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MANEHighAI 9/10

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

HighAI 8/10

Why is Veradermics stock climbing today?

Veradermics Inc (MANE) stock rose 2.5% after reporting positive 12-month data from its Phase 2/3 Study 302 for VDPHL01, showing hair growth in men with mild-to-moderate pattern hair loss. Leerink Partners raised its price target to $150 from $135. The company plans to announce data from a female pattern hair loss study in 2027. The S&P 500 also surged 1.7% on a strong jobs report.

$MANEMedAI 8/10

Veradermics stock rises on 12-month hair growth trial data

Veradermics Inc (NYSE:MANE) shares rose 2.3% after releasing 12-month Phase 2/3 trial data for VDPHL01, an oral minoxidil formulation. Twice-daily treatment showed a 43.9 hairs/cm2 increase, while once-daily showed 29.7 hairs/cm2. 89.1% of twice-daily participants reported visible hair coverage improvement. The treatment was well-tolerated with no serious adverse events.

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.